SearcherWire feed · Explore by industry & state · Buyer directory
Across our public data, Pharma & Life Sciences has 67 publicly announced deals (latest 2026-10-15); 1 buyer whose public criteria mention this industry. The most active states are Pennsylvania (1), Illinois (1).
Pharma & Life Sciences · Core · <$50M EV · Announced 2026-10-15
Currier Plastics rebranded to Alentra, a full-service healthcare and life sciences CDMO.
Source: sheridancp.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2026-09-09
Edgewater Capital Partners sold Prolytix to VION Biosciences.
Source: edgewatercapital.com/news/
Pharma & Life Sciences · Announced 2026-08-27
Provided $11 million healthcare receivables facility.
Source: ecapital.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2026-08-04
Investment in Carolina Components Group, a supplier for biopharmaceutical manufacturers.
Source: sheridancp.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2026-07-29
Life Science Connect expanded its live event reach by acquiring Precision Medicine World Conference.
Source: latticeworkcapital.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2026-06-30
LCM portfolio company Life Science Connect acquired CDMO Live & PharmaSource.
Source: latticeworkcapital.com/news/
Pharma & Life Sciences · Announced 2026-03-31
Raised $10 million Series A for its clinical AI platform.
Source: noromoseley.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2026-01-08
CBCC Global Research rebranded to REV Clinical.
Source: edgewatercapital.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2025-12-26
Verista acquired Integral Solutions to expand automation and validation capabilities.
Source: lightviewcapital.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2025-11-21
AI-powered intelligence platform for life sciences secured Series B financing.
Pharma & Life Sciences · Announced 2025-07-07
Senior secured credit facility to support platform formation and acquisitions.
Source: silverview.com/news
Pharma & Life Sciences · Core · <$50M EV · Announced 2025-06-13
Mobile fleet maintenance provider focused on on-site repair and diagnostics.
Source: roeblingcp.com/portfolio/
Pharma & Life Sciences · Core · <$50M EV · Announced 2025-06-13
Mobile fleet maintenance provider focused on on-site repair and diagnostics.
Source: roeblingcp.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2025
Medical communications and commercialization services for biopharma, specializing in rare disease.
Source: brydon.com/portfolio
Pharma & Life Sciences · Core · <$50M EV · Announced 2025
Equity investment in SaaS company providing auto-body diagnostics and education.
Pharma & Life Sciences · Core · <$50M EV · Announced 2024-12-03
Falcon invested in Ora Clinical, an Ophthalmology CRO.
Pharma & Life Sciences · Announced 2024-10-14
Calibre Scientific acquired Invitech, a UK supplier of in-vitro diagnostics and research kits.
Pharma & Life Sciences · Announced 2024-10-01
Calibre Scientific acquired QMX Laboratories, a UK provider of reference standards and chromatography consumables.
Pharma & Life Sciences · Extended · $50–300M EV · Announced 2024-06-06
Aterian acquired Contract Pharmaceuticals Limited.
Source: aterianpartners.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2024-05-31
Verista acquired ILB Enterprises to enhance pharmacovigilance and compliance.
Source: lightviewcapital.com/news/
Pharma & Life Sciences · Announced 2024-04-16
Provides $33 million liquidity to support growth initiatives.
Source: greatrockcapital.com/news
Pharma & Life Sciences · Announced 2024-03-14
Pace® Life Sciences acquired a New Jersey laboratory from Curia.
Source: auroracap.com/News
Pharma & Life Sciences · Announced 2024-01-01
Acquired by QuVa Pharma.
Source: noromoseley.com/portfolio/
Pharma & Life Sciences · Announced 2023-08-01
Clinical trial research company serving pharmaceutical and biotech companies.
Source: vss.com/portfolio
Pharma & Life Sciences · Core · <$50M EV · Announced 2023-06
Sale of an institutional pharmacy serving long term care agencies.
Pharma & Life Sciences · Announced 2023-03-07
Pace® Analytical Services acquired Alpha Analytical Laboratories.
Source: auroracap.com/News
Pharma & Life Sciences · Core · <$50M EV · Announced 2023
Investment in clinical trial services.
Source: reynoldaequity.com/portfolio/
Pharma & Life Sciences · Core · <$50M EV · Announced 2022-05-24
Verista was named Most Promising Life Sciences Solution Company.
Source: lightviewcapital.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2022-03-30
Verista invested in Delta PM.
Source: lightviewcapital.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2022
Five Points Capital current investment in BlueRidge Life Sciences.
Source: fivepointscapital.com/portfolio/
Pharma & Life Sciences · Core · <$50M EV · Announced 2021-12-15
MiQ Partners acquired CKC, expanding into the life sciences industry.
Source: resiliencecapital.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2021-02-02
Lightview Capital backed Verista invested in Hawkins Point.
Source: lightviewcapital.com/news/
Pharma & Life Sciences · Core · <$50M EV · Announced 2021
Investment in biopharma laboratory instrument services.
Source: reynoldaequity.com/portfolio/
Pharma & Life Sciences · Announced 2020-12-08
Pace Analytical® expanded CDMO capabilities with the acquisition of Bio-Concept Laboratories.
Source: auroracap.com/News
Pharma & Life Sciences · Announced 2020-08-25
Pace Analytical® acquired Emerson Resources, Inc., adding clinical trial material production capabilities.
Source: auroracap.com/News
Pharma & Life Sciences · Announced 2020
Provider of strategic consulting services to biotech and pharmaceutical industries.
Pharma & Life Sciences · Core · <$50M EV · Announced 2019-09
Caymus Equity exited its investment in Medical Laboratory Diagnostics.
Source: caymusequity.com/news
Pharma & Life Sciences · Announced 2019-06-01
Mini Pharmacy distributes diabetic supplies and equipment.
Source: angelesequity.com/portfolio
Pharma & Life Sciences · Core · <$50M EV · Announced 2019-04
Med Labs acquired Mercy Diagnostics.
Source: caymusequity.com/news
Pharma & Life Sciences · Core · <$50M EV · Announced 2018
Investment in clinical site services for CNS disorders.
Source: reynoldaequity.com/portfolio/
Pharma & Life Sciences · Core · <$50M EV · Announced 2012-03-09
Harren formed a sleep disorder diagnostics platform and completed three acquisitions.
Source: harrenequity.com/News.aspx
Pharma & Life Sciences · Core · <$50M EV · Announced 2012
Five Points Capital exited investment in ASL Pharmacy.
Source: fivepointscapital.com/portfolio/
Pharma & Life Sciences · Core · <$50M EV · Announced 2010
Investment in private-label pharmaceutical manufacturing.
Source: reynoldaequity.com/portfolio/
Pharma & Life Sciences · Core · <$50M EV · Announced 2006
Investment in private-label pharmaceutical manufacturing.
Source: reynoldaequity.com/portfolio/
Pharma & Life Sciences · Core · <$50M EV · Announced 2001
Investment in private-label pharmaceutical manufacturing.
Source: reynoldaequity.com/portfolio/
Pharma & Life Sciences · Pennsylvania · Announced
Analytical testing, consulting, and field sampling services.
Source: tecum.com/portfolio-overview/
Pharma & Life Sciences · Core · <$50M EV · Announced
Manufacturer and distributor of life sciences consumables.
Pharma & Life Sciences · Core · <$50M EV · Announced
Provider of sleep disorder diagnostic and therapeutic solutions.
Source: harrenequity.com/Portfolio.aspx
Pharma & Life Sciences · Core · <$50M EV · Announced
Institutional pharmacy providing pharmaceutical products to long term care agencies.
Pharma & Life Sciences · Core · <$50M EV · Announced
Healthcare engagement agency for pharmaceutical and biotech companies.
Pharma & Life Sciences · Core · <$50M EV · Announced
Business and consulting services for life sciences.
Source: wvcapital.com/portfolio
Pharma & Life Sciences · Core · <$50M EV · Announced
Electronic claims, payment, and clinical information transmittal.
Source: wvcapital.com/portfolio
Pharma & Life Sciences · Core · <$50M EV · Announced
Engineering, development, and compliance for life sciences.
Source: wvcapital.com/portfolio
Pharma & Life Sciences · Core · <$50M EV · Announced
Reverse logistics for processing unsaleable pharmaceutical products.
Source: wvcapital.com/portfolio
Pharma & Life Sciences · Core · <$50M EV · Announced
Direct-to-patient marketing for life sciences.
Source: wvcapital.com/portfolio
Pharma & Life Sciences · Extended · $50–300M EV · Announced
Past investment.
Source: vesterracap.com/portfolio/
Pharma & Life Sciences · Extended · $50–300M EV · Announced
Past investment.
Source: vesterracap.com/portfolio/
Pharma & Life Sciences · Extended · $50–300M EV · Announced
Formed through combination of Tabula Rasa HealthCare and ExactCare Pharmacy.
Source: nautic.com/
Pharma & Life Sciences · Core · <$50M EV · Announced
Investment in an executive search firm for healthcare and life science.
Source: starmountaincapital.com/current-prior-portfolio-companies/
Pharma & Life Sciences · Announced
Kanbrick acquired Laboratory Testing Inc. in partnership with McVaugh and Hiller families.
Source: kanbrick.com/press-releases/
Showing 60 of 68 items; the rest are in the feed.
Aerospace & DefenseAgricultureAutomotiveBehavioral HealthBuilding ProductsBusiness ServicesChemicals & MaterialsConstructionConsumer Products & BrandsCybersecurityDentalDistribution & WholesaleEducation & TrainingEnergy & UtilitiesEngineering & TestingEnvironmental & WasteFacility ServicesFinancial ServicesFood & BeverageGeneral / DiversifiedGovernment & Public SectorHVAC, Plumbing & ElectricalHealthcare ServicesHome & Commercial ServicesIT & Managed ServicesIndustrial ManufacturingInsuranceLandscaping & OutdoorLogistics & TransportationMedia & Marketing TechMedical DevicesPhysical Therapy & RehabReal Estate ServicesRestaurants & HospitalityRetail & E-commerceSoftware & SaaSStaffing & HRTelecom & InfrastructureVeterinary & Pet
Public data only, restated in our own words; every item links to its public source. Not an introduction, matching, or brokerage service, and not investment advice. SearcherWire is independent of, and not offered through, any broker-dealer. Nothing here is an offer to buy or sell any business or security, a solicitation of such an offer, or a recommendation, and SearcherWire makes no deal introductions. Corrections